Study of Pemetrexed+Platinum Chemotherapy With or Without Cosibelimab in First Line Metastatic Non-squamous NSCLC

PHASE3TerminatedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

December 8, 2021

Primary Completion Date

December 30, 2023

Study Completion Date

December 30, 2023

Conditions
Metastatic Non-squamous Non Small Cell Lung Cancer
Interventions
DRUG

Cosibelimab

IV infusion

DRUG

Cisplatin

IV infusion

DRUG

Carboplatin

IV infusion

DRUG

Pemetrexed

IV infusion

DIETARY_SUPPLEMENT

Folic acid 350-1000 μg

Orally; at least 5 doses of folic acid must be taken during the 7 days preceding the first dose of pemetrexed, and folic acid dosing must continue during the full course of therapy and for 21 days after the last dose of pemetrexed.

DIETARY_SUPPLEMENT

Vitamin B12 1000 μg

Intramuscular injection in the week preceding the first dose of pemetrexed and once every 3 cycles thereafter. Subsequent vitamin B12 injections may be given the same day as pemetrexed administration.

DRUG

Dexamethasone 4mg

For prophylaxis; orally twice per day (or equivalent). Taken the day before, day of, and day after pemetrexed administration.

Trial Locations (22)

Unknown

Research Site, Vitória

Research Site, Tbilisi

Research Site, Kota Bharu

Research Site, Wellington

Research Site, Lima

Research Site, Arkhangelsk

Research Site, Chelyabinsk

Research Site, Kaliningrad

Research Site, Kazan'

Research Site, Kursk

Research Site, Kuzmolovskiy

Research Site, Moscow

Research Site, Nizhny Novgorod

Research Site, Novosibirsk

Research Site, Omsk

Research Site, Saint Petersburg

Research Site, Samara

Research Site, Sochi

Research Site, Tomsk

Research Site, Volgograd

Research Site, Pretoria

Research Site, Chiang Mai

Sponsors
All Listed Sponsors
lead

Checkpoint Therapeutics, Inc.

INDUSTRY

NCT04786964 - Study of Pemetrexed+Platinum Chemotherapy With or Without Cosibelimab in First Line Metastatic Non-squamous NSCLC | Biotech Hunter | Biotech Hunter